This post was originally published on this site
WASHINGTON — The National Institutes of Health is launching a late-stage clinical trial to determine whether three drugs used for controlling immune systems could be used to treat respiratory distress and organ failure in severely ill Covid-19 patients.
The NIH study will evaluate two drugs already on the market, Johnson & Johnson’s JNJ, -0.61% Remicade and Bristol-Myers Squibb Co.’s BMY, -0.95% Orencia, along with an investigational drug called CVC from AbbVie Inc. ABBV, -0.97%
